GlaxoSmithKline

EMA approves GSK’s Malaria vaccine

Wednesday, July 29, 2015

GlaxoSmithKline (GSK) has received a positive opinion for its malaria vaccine candidate from the Committee for Medicinal Products for Human Use (CHMP) of the EMA. The vaccine candidate Mosquirix (RTS,S) is the first QS-21 Stimulon containing product to receive a positive regulatory decision.

[Read More]

Tekmira changes name to Arbutus Biopharma, a hepatitis B solutions company

Wednesday, July 22, 2015

Tekmira Pharmaceuticals, headquartered in Vancouver, Canada, plans to change its corporate name to Arbutus Biopharma, a therapeutic solutions company focused on developing a cure for chronic hepatitis B virus infection (HBV), to be effective on or before Aug. 3. The name change affirms the successful integration of OnCore BioPharma and Tekmira Pharmaceuticals into a combined company with the singular goal of delivering a cure for chronic HBV. The combined entity currently fields a large portfolio of HBV product candidates in the industry.

[Read More]

MRC, GSK, five U.K. universities collaborate on difficult disease areas

Wednesday, July 15, 2015

Medical Research Council (MRC), GlaxoSmithKline and five U.K. universities are collaborating on difficult disease areas. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases.

[Read More]

Zogenix expands senior leadership team

Friday, July 10, 2015

Zogenix, a pharmaceutical company developing and commercializing products for the treatment of central nervous system (CNS) disorders, has appointed Gail M. Farfel, Ph.D., executive vice president and chief development officer, and Thierry Darcis, M.D., M.B.A., executive vice president and general manager, Europe.

[Read More]

GSK launches Altius Institute for Biomedical Sciences

Wednesday, June 17, 2015

GlaxoSmithKline is launching the Altius Institute for Biomedical Sciences, an independent, nonprofit research institute in Seattle. Altius will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s “operating system” functions in health and disease. GSK expects to capitalize on rapid progress in understanding gene control to select and validate better drug targets, and to accelerate many key aspects of developing new medicines.

[Read More]

Report: Innovation trends in treatments for rare diseases and widespread conditions

Wednesday, June 17, 2015

The antibiotics market is at risk of losing another decade to inadequate levels of research and innovation, according to international intellectual property firm Marks & Clerk’s new report From rare to routine—medicines for rare diseases, vaccines and antibiotics. Research highlights the striking difference between research levels into rare diseases, vaccines and antibiotics across the globe.

[Read More]

Society for Clinical Research Sites launches program for Asia-Pac Site Solutions Summit

Wednesday, June 17, 2015

The Society for Clinical Research Sites (SCRS), a global trade organization fully dedicated to representing the interests of clinical research sites, has announced a program for the 2015 Asia-Pac Site Solutions Summit. The Asia-Pac Site Solutions Summit will be July 30-31, 2015 in Melbourne, Australia. The Summit is open to clinical research investigators, site executives and industry stakeholders.

[Read More]